Condition
Safety Evaluation of Escalating Doses
Total Trials
3
Recruiting
0
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Completed2
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT07546149Phase 1CompletedPrimary
A Multiple Ascending Dose Study of LW402 in Healthy Volunteers
NCT06633562Phase 1Active Not Recruiting
A Study to Test the Effects of Nezavist at Different Doses in Healthy Adults
NCT01485146Phase 1CompletedPrimary
A Multiple Ascending Dose Study of ETC-1002 in Healthy Subjects
Showing all 3 trials